Meeting
2019 ASCO Annual Meeting
Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden analysis.
Authors
Kirsten Timms
Myriad Genetics, Inc., Salt Lake City, UT
Kirsten Timms , Andrey Zharkikh , Michael Perry , Nicolai Birkbak , Zoltan Szallasi , Alexander Gutin , Andrea Richardson , Jerry Lanchbury
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2634)
DOI
10.1200/JCO.2019.37.15_suppl.2634
Abstract #
2634
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
POLE variant phenotypic classification to enable identification of patients with colorectal cancer (CRC) who may benefit from immune checkpoint inhibition (ICI).
First Author: Rachel Beth Keller
Poster
2023 ASCO Annual Meeting
Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.
First Author: Ryan M. Kahn
Poster
2021 ASCO Annual Meeting
Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC).
First Author: Takaya Ikeda
Poster
2019 Genitourinary Cancers Symposium
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
First Author: Matthew Labriola